Vincenti Flavio, de Andrés Amado, Becker Thomas, Choukroun Gabriel, Cole Edward, González-Posada José M, Kumar Mysore A, Moore Richard, Nadalin Silvio, Nashan Björn, Rostaing Lionel, Saito Kazuhide, Yoshimura Norio
Transplant Service, University of California, San Francisco, San Francisco, USA.
Transpl Int. 2006 Jun;19(6):446-57. doi: 10.1111/j.1432-2277.2006.00321.x.
Addition of interleukin-2 receptor antagonist (IL-2RA) induction to calcineurin inhibitor (CNI)-based regimens reduces biopsy-proven acute rejection by 30-40%. IL-2RA induction facilitates early withdrawal of steroids, and supports the safe use of reduced-exposure CNI or delayed CNI introduction. IL-2RAs and rabbit antithymocyte globulin (Thymoglobulin) show comparable efficacy in patients at standard or low immunologic risk, but the adverse event profiles of lymphocyte-depleting agents are less favorable. IL-2RAs, uniquely, provide effective immunosuppression with similar tolerability to placebo.
在基于钙调神经磷酸酶抑制剂（CNI）的方案中添加白细胞介素-2受体拮抗剂（IL-2RA）诱导治疗可使活检证实的急性排斥反应减少30%-40%。IL-2RA诱导治疗有助于早期停用类固醇，并支持安全使用低剂量CNI或延迟引入CNI。在标准或低免疫风险的患者中，IL-2RA和兔抗胸腺细胞球蛋白（即胸腺球蛋白）显示出相当的疗效，但淋巴细胞清除剂的不良事件谱不太有利。独特的是，IL-2RA能提供有效的免疫抑制，其耐受性与安慰剂相似。
